Research - Research groups - GC26 Clinical virology and zoonosis

GC26 Clinical virology and zoonosis

The research group "Clinical Virology and Zoonoses" is a consolidated group of the IMIBIC whose research activity is part of IMIBIC’s Scientific Program "Infectious diseases, immunological and organ transplantation". Our main research lines include the study of diagnostic and therapeutic tools and the design of prevention strategies for viral and zoonotic diseases prevalent in our environment that pose a health risk to the population. The objectives of our research are the acquisition and translation of knowledge into health problem solutions and promotion of the concept of One Health. These objectives are achieved by implementing collaborative, multidisciplinary research activities to solve health problems common to animals and humans.

The group successfully develops various lines of research in the field of HIV infection as well as co-infection with HIV / HCV. Our efforts in this area are demonstrated by more than 80 publications in international journals with a high impact factor that has generated an accumulated impact factor of over 350 points and two innovation patents registered in the last five years. In the context of zoonotic diseases, more than fifteen articles have been published, accumulating an impact factor of more than 50 points in only 5 years.

Our group is also part of the AIDS Research Network (RIS, RD16 / 0025/0034) formed by numerous groups in Spain consolidated in HIV research.

Research Lines

Immunology, pathogenesis, treatment and prevention of HIV infection

Our line of research on HIV infection includes studies aimed at the optimization of ART, pharmacokinetics, pharmacogenetics, the impact of the viral reservoir, AIDS and non-AIDS events related to HIV infection, fatty liver disease in the HIV-infected patient, as well as studies evaluating innate immunity against the virus.

Immunology, pathogenesis, treatment and prevention of HCV infection (especially HIV / HCV coinfection)

This line includes studies of the natural history of liver fibrosis and cirrhosis, development of hepatocellular carcinoma, HCV reinfections, relapse after end of antiviral treatment, genetic and immunological markers related to natural history and response to treatment of infection by HCV, as well as studies of baseline viral resistance and its impact on response rates to treatment. At the same time, this line also includes evaluation studies of the situation of HIV / HCV coinfection in Andalusia. In this activity, our group is coordinator of an Andalusian cohort.

Immunology, pathogenesis, treatment and prevention of classic and emerging zoonotic diseases

This line includes prospective studies of the prevalence of hepatitis E virus infection in patients in different clinical situations (acute hepatitis, fever of intermediate duration, HIV infection, pregnancy and so on), longitudinal studies to assess the prevalence of HEV infection among blood donors, evaluations of the prevalence of HEV infection in farm and game species, identification of sources of HEV infection of animal origin in our environment, as well as the identification of animal reservoirs of various pathogens.

Networks

AIDS Research Network (RIS)

HEVnet (ECDC: NP/2016/OCS/7892/01)

Keywords

HIV
HCV
HEV
infection
AIDS
ART
CD4
hepatitis
pathogens
fibrosis
cirrhosis
innate immunity
pharmacogenomics
viral reservoir
zoonoses

Additional Information

Recent publications

Caballero-Gomez J, Jimenez-Ruiz S, Lopez-Lopez P, Vicente J, Risalde MA, Cano-Terriza D, Frias M, Barasona JA, Rivero A, Garcia-Bocanegra I, Rivero-Juarez A; Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 2019 Sep;66(5):1803-1808. doi: 10.1111/tbed.13251. IF: 3,554. D1

Caballero-Gomez J, Rivero-Juarez A, Cano-Terriza D, Risalde MA, Lopez-Lopez P, Frias M, Jimenez-Ruiz S, Rivero A, Garcia-Bocanegra I; Survey for Hepatitis E virus infection in non-human primates in zoos in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 2019 Jul;66(4):1771-1775. doi: 10.1111/tbed.13196. IF: 3,504. D1

Rivero-Juarez A, Lopez-Lopez P, Frias M, Rivero A; Hepatitis E Infection in HIV-Infected Patients. FRONTIERS IN MICROBIOLOGY. 2019 Jun 26;10:1425. doi: 10.3389/fmicb.2019.01425. IF: 4,259. Q1.

Lopez-Lopez P, Rivero-Juarez A, Frias M, Machuca I, Caballero-Gomez J, Olivas I, Camacho A, Risalde MD, Garcia-Bocanegra I, Rivero A; Mutations in the Progesterone Receptor (PROGINS) May Reduce the Symptoms of Acute Hepatitis E and Protect Against Infection. FRONTIERS IN MICROBIOLOGY. 2019 Nov 7;10:2617. doi: 10.3389/fmicb.2019.02617. IF: 4,259. D2 Q1.

Rivero-Juarez A, Jarilla-Fernandez M, Frias M, Madrigal-Sanchez E, Lopez-Lopez P, Andujar-Troncoso G, Machuca I, Camacho A, Munoz-Valbuena P, Rivero A; Hepatitis E virus in Spanish donors and the necessity for screening. JOURNAL OF VIRAL HEPATITIS. 2019 May;26(5):603-608. doi: 10.1111/jvh.13064. IF: 4,016. Q1.

Frias M, Rivero-Juarez A, Tellez F, Palacios R, Jimenez-Arranz A, Pineda JA, Merino D, Gomez-Vidal MA, Perez-Camacho I, Camacho A, Rivero A; Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. SCIENTIFIC REPORTS. 2019 Aug 29;9(1):12507. doi: 10.1038/s41598-019-48966-9. IF: 4,011. Q1

Lopez-Lopez P, Frias M, Camacho A, Rivero A, Rivero-Juarez A; Human Immunodeficiency Virus Infected Patients are Not at Higher Risk for Hepatitis E Virus Infection: A Systematic Review and Meta-Analysis. MICROORGANISMS. 2019 Nov 26;7(12). pii: E618. doi: 10.3390/microorganisms7120618. IF: 4,167. Q2

Dr. Antonio Rivero Román

Principal Investigator

Projects

Active in 2019

Regional

Frias Casas, M. Optimización del Diagnóstico Molecular de la Infección Por el Virus de la Hepatitis E Mediante el Uso de Una Técnica de PCR (Proyecto Panhenotypic). Funding Agency: Regional Ministry of Equality, Health and Social Policies (CISPS). Reference: PIN-0477-2017.

Rivero Juárez, Antonio. Biologia molecular del virus de la hepatitis E; Funding agency: FIBICO. Fundación para la investigación biomédica de Córdoba; Reference: EF-0003-2018-FIB.

National

Rivero Román, A. Andalusian prospective follow-up cohort of chronically HCV infected patients co-infected with HIV. National Institute of Health Carlos III (ISCIII). Reference: PI15/01017.

Rivero Juarez A. Impact of the acute Hepatitis e Virus Infection in HIV Infected Patients. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI16/01297.

Rivero Román, A. AIDS Research Network (RIS). Funding agency: National Institute of Health Carlos III (ISCIII). Reference: RD16/0025/0034.

Rivero Román, A. Evaluación de la influencia de la enfermedad hepática grasa no alcohólica sobre eventos clínicos y mortalidad de los pacientes infectados por VIH. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: PI18/01270.

Rivero Juárez A. Contratos Miguel Servet - Antonio Rivero Juárez (Proyecto Mochila); Funding Agency: National Institute of Health Carlos III (ISCIII). Reference: LACP18/00111.

Publications

2019

Perez AB, Chueca N, Garcia-Deltoro M, Martinez-Sapina AM, Lara-Perez MM, Garcia-Bujalance S, Aldamiz-Echevarria T, Vera-Mendez FJ, Pineda JA, Casado M, Pascasio JM, Salmeron J, Alados-Arboledas JC, Poyato A, Tellez F, Rivero-Juarez A, Merino D, Vivancos-G; High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. JOURNAL OF HEPATOLOGY. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022.
IF: 18,946
D: 1

Vrancken B, Cuypers L, Perez AB, Chueca N, Anton-Basantas J, de la Iglesia A, Fuentes J, Pineda JA, Tellez F, Bernal E, Rincon P, Von Wichman MA, Fuentes A, Vera F, Rivero-Juarez A, Jimenez M, Vandamme AM, Garcia F; Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. JOURNAL OF HEPATOLOGY. 2019 Dec;71(6):1270-1272. doi: 10.1016/j.jhep.2019.08.010.
IF: 18,946
Q:1 D: 1

Macias J, Morano LE, Tellez F, Granados R, Rivero-Juarez A, Palacios R, Rios MJ, Merino D, Perez-Perez M, Collado A, Figueruela B, Morano A, Freyre-Carrillo C, Martin JM, Rivero A, Garcia F, Pineda JA; Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. JOURNAL OF HEPATOLOGY. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018.
IF: 15,04
D: 1

Jimenez-Sousa MA, Jimenez JL, Fernandez-Rodriguez A, Brochado-Kith O, Bellon JM, Gutierrez F, Diez C, Bernal-Morell E, Viciana P, Munoz-Fernandez MA, Resino S, Moreno S, del Amo J, Dalmau D, Navarro ML, Gonzalez MI, Blanco JL, Garcia F, Rubio R, Iribarren; VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Naive HIV-Infected Patients. JOURNAL OF CLINICAL MEDICINE. 2019 Mar 5;8(3). pii: E311. doi: 10.3390/jcm8030311.
IF: 5,688
D: 1

Fresco-Taboada A, Risalde MA, Gortazar C, Tapia I, Gonzalez I, Venteo A, Sanz A, Rueda P; A lateral flow assay for the rapid diagnosis of Mycobacterium bovis infection in wild boar. TRANSBOUNDARY AND EMERGING DISEASES. 2019 Sep;66(5):2175-2179. doi: 10.1111/tbed.13260.
IF: 3,554
D: 1

Garcia-Bocanegra I, Camacho-Sillero L, Risalde MA, Dalton KP, Caballero-Gomez J, Aguero M, Zorrilla I, Gomez-Guillamon F; First outbreak of myxomatosis in Iberian hares (Lepus granatensis). TRANSBOUNDARY AND EMERGING DISEASES. 2019 Nov;66(6):2204-2208. doi: 10.1111/tbed.13289.
IF: 3,554
D: 1

Garcia-Bocanegra I, Rivero A, Caballero-Gomez J, Lopez-Lopez P, Cano-Terriza D, Frias M, Jimenez-Ruiz S, Risalde MA, Gomez-Villamandos JC, Rivero-Juarez A; Hepatitis E virus infection in equines in Spain. TRANSBOUNDARY AND EMERGING DISEASES. 2019 Jan;66(1):66-71. doi: 10.1111/tbed.12962
IF: 3,554
D: 1

Roy A, Tome I, Romero B, Lorente-Leal V, Infantes-Lorenzo JA, Dominguez M, Martin C, Aguilo N, Puentes E, Rodriguez E, de Juan L, Risalde MA, Gortazar C, Dominguez L, Bezos J; Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis. VETERINARY RESEARCH. 2019 Oct 15;50(1):82. doi: 10.1186/s13567-019-0702-7.
IF: 3,117
D: 1

Camacho-Sillero L, Caballero-Gomez J, Gomez-Guillamon F, Martinez-Padilla A, Aguero M, San Miguel E, Zorrilla I, Rayas E, Talavera V, Garcia-Bocanegra I; Monitoring of the novel rabbit haemorrhagic disease virus type 2 (GI.2) epidemic in European wild rabbits (Oryctolagus cuniculus) in southern Spain, 2013-2017. 237. 108361. VETERINARY MICROBIOLOGY. 2019 Oct;237:108361. doi: 10.1016/j.vetmic.2019.07.013.
IF: 2,791
D: 1

Thomas J, Infantes-Lorenzo JA, Moreno I, Cano-Terriza D, de Juan L, Garcia-Bocanegra I, Dominguez L, Dominguez M, Gortazar C, Risalde MA; Validation of a new serological assay for the identification of Mycobacterium tuberculosis complex-specific antibodies in pigs and wild boar. PREVENTIVE VETERINARY MEDICINE. 2019 Jan 1;162:11-17. doi: 10.1016/j.prevetmed.2018.11.004.
IF: 2,302
D: 1

Jaimes-Bernal C, Rallon N, Benito JM, Omar M, Gomez-Vidal MA, Marquez FJ, Sanchez-Arcas B, Trujillo M, Royo JL, Saulle I, Biasin M, Rivero-Juarez A, Caruz A; A Knockout IFNL4 Variant Is Associated With Protection From Sexually Transmitted HIV-1 Infection. JOURNAL OF INFECTIOUS DISEASES. 2019 Feb 15;219(5):772-776.
IF: 5,045
Q: 1

Corma-Gomez A, Morano L, Tellez F, Rivero-Juarez A, Real LM, Alados JC, Rios-Villegas MJ, Vera-Mendez FJ, Munoz RP, Geijo P, Macias J, Pineda JA; HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS. 2019 Jun 1;33(7):1167-1174. doi: 10.1097/QAD.0000000000002186.
IF: 4,914
Q: 1

Resino S, Navarrete-Munoz MA, Blanco J, Pacheco YM, Castro I, Berenguer J, Santos J, Vera-Mendez FJ, Gorgolas M, Jimenez-Sousa MAA, Benito JM, Rallon N. (CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network Project RIS/EPICLIN 10_201; IL7RA rs6897932 Polymorphism Is Associated with Better CD4(+) T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy. BIOMOLECULES. 2019 Jun 16;9(6). pii: E233. doi: 10.3390/biom9060233.
IF: 4,694
Q: 1

Machuca I, Gutierrez-Gutierrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Perez E, Perez-Nadales E, Caston JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual A, Martinez-Martinez L, Rodriguez-Bano J, Torre-Cisneros J, Salamanca E, ; External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2019 Oct;54(4):442-448. doi: 10.1016/j.ijantimicag.2019.07.017.
IF: 4,615
Q: 1

Real LM, Fernandez-Fuertes M, Saez ME, Rivero-Juarez A, Frias M, Tellez F, Santos J, Merino D, Moreno-Grau S, Gomez-Salgado J, Gonzalez-Serna A, Corma-Gomez A, Ruiz A, Macias J, Pineda JA; A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). LIVER INTERNATIONAL. 2019 Oct;39(10):1918-1926. doi: 10.1111/liv.14177.
IF: 4,5
Q: 1

Rodriguez-Gomez J, Perez-Nadales E, Gutierrez-Gutierrez B, Machuca I, Martinez-Martinez L, Rivera F, Cano A, Caston JJ, Robles JC, de la Fuente C, Rodriguez-Lopez F, Rodriguez-Bano J, Torre-Cisneros J; Prognosis of urinary tract infection caused by KPC-producing Klebsiella pneumoniae: The impact of inappropriate empirical treatment. JOURNAL OF INFECTION. 2019 Sep;79(3):245-252. doi: 10.1016/j.jinf.2019.06.014.
IF: 5,099
Q: 1

Merchante N, Figueruela B, Rodriguez-Fernandez M, Rodriguez-Arrondo F, Revollo B, Ibarra S, Galindo MJ, Merino E, Montero M, Tellez F, Garcia-Deltoro M, Rivero-Juarez A, Delgado-Fernandez M, Rios-Villegas MJ, Aguirrebengoa K, Garcia MA, Portu J, Vera-Mend; Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS. 2019 Feb 1;33(2):269-278. doi: 10.1097/QAD.0000000000002065.
IF: 4,499
Q: 1

Rivero-Juarez A, Lopez-Lopez P, Frias M, Rivero A; Hepatitis E Infection in HIV-Infected Patients. FRONTIERS IN MICROBIOLOGY. 2019 Jun 26;10:1425. doi: 10.3389/fmicb.2019.01425.
IF: 4,259
Q: 1

Neukam K, Fernandez MD, Quero JH, Rivero-Juarez A, Llaves-Flores S, Onate FJ, Gutierrez-Valencia A, Espinosa N, Viciana P, Lopez-Cortes LF; Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2019 May 1;81(1):e1-e5. doi: 10.1097/QAI.0000000000001990.
IF: 4,116
Q:1

Macias J, Granados R, Tellez F, Merino D, Perez M, Morano LE, Palacios R, Paniagua M, Frias M, Merchante N, Pineda JA, Merchante N, Mancebo M, Rivero A, Rivero-Juarez A, Marquez M, Ojeda G, Santos J, Romero J, de los Santos I, Omar M, Gomez-Vidal MA, Prad; Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. JOURNAL OF VIRAL HEPATITIS. 2019 Jan;26(1):16-24. doi: 10.1111/jvh.12990.
IF: 4,016
Q: 1

Macias J, Tellez F, Rivero-Juarez A, Palacios R, Morano LE, Merino D, Collado A, Garcia-Fraile L, Omar M, Pineda JA, Merchante N, Mancebo M, Rivero A, Marquez M, Romero J, de los Santos I, Gomez-Vidal MA; Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients. JOURNAL OF VIRAL HEPATITIS. 2019 Jan;26(1):48-54. doi: 10.1111/jvh.13003.
IF: 4,016
Q: 1

Real LM, Macias J, Rivero-Juarez A, Tellez F, Merino D, Moreno-Grau S, Orellana A, Gomez-Salgado J, Saez ME, Frias M, Corma-Gomez A, Merchante N, Ruiz A, Caruz A, Pineda JA, Fernandez-Fuertes M, Iglesias M, Rincon P; Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection. SCIENTIFIC REPORTS. 2019 Jun 21;9(1):9054. doi: 10.1038/s41598-019-45389-4.
IF: 4,011
Q: 1

Thomas J, Infantes-Lorenzo JA, Moreno I, Romero B, Garrido JM, Juste R, Dominguez M, Dominguez L, Gortazar C, Risalde MA; A new test to detect antibodies against Mycobacterium tuberculosis complex in red deer serum. VETERINARY JOURNAL. 2019 Feb;244:98-103. doi: 10.1016/j.tvjl.2018.12.021.
IF: 1,919
Q: 1

Cano-Terriza D, Almeria S, Caballero-Gomez J, Diaz-Cao JM, Jimenez-Ruiz S, Dubey JP, Garcia-Bocanegra I; Serological survey of Toxoplasma gondii in captive nonhuman primates in zoos in Spain. COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES. 2019 Aug;65:54-57. doi: 10.1016/j.cimid.2019.04.002.
IF: 1,871
Q: 1

Perez AB, Chueca N, Macias J, Pineda JA, Salmeron J, Rivero-Juarez A, Hidalgo-Tenorio C, Espinosa MD, Tellez F, Von-Wichmann MA, Omar M, Santos J, Hernandez-Quero J, Anton JJ, Collado A, Lozano AB, Garcia-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales; Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLOS ONE. 2019 Aug 30;14(8):e0221231. doi: 10.1371/journal.pone.0221231.
IF: 3,776
Q: 2

Rivero-Juarez A, Tellez F, Castano-Carracedo M, Merino D, Espinosa N, Santos J, Macias J, Paniagua-Garcia M, Zapata-Lopez A, Collado A, Gomez-Vidal MA, Perez-Stachowski J, Munoz-Medina L, Fernandez-Fuertes E, Rivero A; Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients. HIV MEDICINE. 2019 Jul;20(6):359-367. doi: 10.1111/hiv.12715.
IF: 3,734
Q: 2

Alejos B, Suarez-Garcia I, Bisbal O, Iribarren JA, Asensi V, Gorgolas M, Muga R, Moreno S, Jarrin I. (CoRIS cohort: Jarrin, I; Dalmau, D; Navarro, ML; Gonzalez, MI; Blanco, JL; Garcia, F; Rubio, R; Iribarren, JA; Gutierrez, F; Vidal, F; Berenguer, J; Gonz; Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. PLOS ONE. 2019 Aug 26;14(8):e0221598. doi: 10.1371/journal.pone.0221598
IF: 2,776
Q: 2

Aguilar-Jimenez W, Zapata W, Rivero-Juarez A, Pineda JA, Laplana M, Taborda NA, Biasin M, Clerici M, Caruz A, Fibla J, Rugeles MT; Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability. INFECTION GENETICS AND EVOLUTION. 2019 Sep;73:276-286. doi: 10.1016/j.meegid.2019.05.014.
IF: 2,611
Q: 3

2018

Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Frias M, Briceno J, de la Mata M, Torre-Cisneros J, Rivero A. Prevalence of hepatitis E virus infection in liver donors in Spain. CLINICAL MICROBIOLOGY AND INFECTION. 2018. 24(11)1218-1219.
IF: 6,425
Q: 1 D: 1

Rivero-Juarez A, Frias M, Lopez-Lopez P, Martinez-Peinado A, Risalde MA, Brieva T, Machuca I, Camacho A, Garcia-Bocanegra I, Gomez-Villamandos JC, Rivero A. Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection. ZOONOSES AND PUBLIC HEALTH. 2018. 65 (5) 584-588.
IF: 2,164
Q: 1 D: 1

Lopez-Lopez P, Risalde MD, Frias M, Garcia-Bocanegra I, Brieva T, Caballero-Gomez J, Camacho A, Fernandez-Molera V, Machuca I, Gomez-Villamandos JC, Rivero A, Rivero-Juarez A. Risk factors associated with hepatitis E virus in pigs from different production systems. VETERINARY MICROBIOLOGY. 2018. 224 () 88-92.
IF: 2,791
Q: 1 D: 1

Rivero-Juarez A, Risalde MA, Frias M, Garcia-Bocanegra I, Lopez-Lopez P, Cano-Terriza D, Camacho A, Jimenez-Ruiz S, Gomez-Villamandos JC, Rivero A. Prevalence of hepatitis E virus infection in wild boars from Spain: a possible seasonal pattern?. BMC VETERINARY RESEARCH. 2018.14(1)5
IF: 1,792
Q: 1

Frias M, Rivero-Juarez A, Rodriguez-Cano D, Camacho A, Lopez-Lopez P, Risalde MA, Manzanares-Martin B, Brieva T, Machuca I, Rivero A. HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance. SCIENTIFIC REPORTS. 2018. 8(1) 659.
IF: 4,011
Q: 1

Rivero-Juarez A, Camacho A, Brieva T, Frias M, Lopez-Lopez P, Risalde MA, Machuca I, Caston JJ, Martinez-Peinado A, Rivero A. Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2018. 78(4)437-440.
IF: 3,863
Q: 1

Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2018. 14 (9) 901-910.
IF: 3,487
Q: 2

Frias M, Lopez-Lopez P, Rivero A, Rivero-Juarez A. Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure. BIOMED RESEARCH INTERNATIONAL. 201()9098535.
IF: 2,197
Q: 2

Frias M, Rivero-Juarez A, Lopez-Lopez P, Rivero A. Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. PHARMACOGENOMICS. 2018. 19 (12) 979-995.
IF: 2,265
Q: 3

Rivero A, Perez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lazaro P, Lopez-Aldeguer J, Lozano F, Martinez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2018. 36(5) 268-276.
IF: 1,685
Q: 3

Rivero A, Polo R, Aldeguer JL, Lozano F, Antela A, Arribas JR, Asensi V, Berenguer J, Blanco JR, Casado JL, Clotet B, Crespo M, Domingo P, Duenas C, Gatell JM, Gomez-Sirvent JL, Gonzalez-Garcia J, Iribarren JA, de Quiros JCLB, Cortes LFL, Losa JE, Mallolas J, Marino A, Martinez E, Miro JM, Moreno S, Palacios R, Pasquau J, Pineda JA, Podzamczer D, Portilla J, Poveda E, Pulido F, Rubio R, Santos J, Moreno JS, Sanz JS, Tellez MJ, de la Torre J, Tuset M, Molina JAP. Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017). ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2018. 36 (7) 435-445.
IF: 1,685
Q: 3

Machuca I, Vidal E, de la Torre-Cisneros J, Rivero-Roman A. Tuberculosis in immunosuppressed patients. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2018. 36 (6) 366-374.
IF: 1,685
Q: 3

Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, Amado LEM, Morillas RM, Forns X, Acevedo JMP, Andrade RJ, Rivero A, Carrion JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang GL, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. GASTROENTEROLOGY. 2018. 155(4) 1120-1127.
IF: 19,233
Q: 1 D: 1

Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. CLINICAL MICROBIOLOGY REVIEWS. 2018.31(2)-.
IF: 17,750
Q: 1 D: 1

Amat T, Gutierrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, Garnacho-Montero J, Cisneros JM, Torre-Cisneros J. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. CLINICAL MICROBIOLOGY AND INFECTION. 2018; 24(6):630-634.
IF: 5,394
Q: 1 D: 1

Perez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Marino A, Crespo M, Hernandez-Quero J, Iribarren JA, Gutierrez F, Terron A, Esteban H, Perez-Molina JA. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2018. 73(9) 2444-2451.
IF: 5,113
Q: 1 D: 1

Merchante N, Rivero-Juarez A, Tellez F, Merino D, Rios-Villegas MJ, Villalobos M, Omar M, Rincon P, Rivero A, Perez-Perez M, Raffo M, Lopez-Montesinos I, Palacios R, Gomez-Vidal MA, Macias J, Pineda JA. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2018. 73 (9) 2435-2443.
IF: 5,113
Q: 1 D: 1

Cuypers L, Perez AB, Chueca N, Aldamiz-Echevarria T, Alados JC, Martinez-Sapina AM, Merino D, Pineda JA, Tellez F, Espinosa N, Salmeron J, Rivero-Juarez A, Vivancos MJ, Hontanon V, Vandamme AM, Garcia F. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis. PLOS ONE. 2018.13(7)-.
IF: 2,766
Q: 1

Roy A, Risalde MA, Bezos J, Casal C, Romero B, Sevilla I, Diez-Guerrier A, Rodriguez-Bertos A, Dominguez M, Garrido J, Gortazar C, Dominguez L. Response of goats to intramuscular vaccination with heat-killed Mycobacterium bovis and natural challenge. COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES. 2018. 60() 28-34.
IF: 1,92
Q: 1

Merchante N, Rodriguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, Garcia-Deltoro M, Rivero-Juarez A, Tellez F, Delgado-Fernandez M, Rios-Villegas MJ, Garcia MA, Vera-Mendez FJ, Ojeda-Burgos G, Lopez-Ruz MA, Metola L, Omar M, Aleman-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macias J, Pineda JA. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS. 201 32 (11) 1423-1430.
IF: 4,914
Q: 1

2017

Rivero-Juarez A, Frias M, Lopez-Lopez P, Risalde MD, Brieva T, Machuca I, Camacho A, Martinez-Peinado A, Gomez-Villamandos JC, Rivero A.Hepatitis E Virus (HEV) Infection in Anti-HEV Immunoglobulin G-Carrying Patients After Successful Hepatitis C Virus Treatment: Reactivation or Reinfection?. CLINICAL INFECTIOUS DISEASES. 2017.64(7):964-966.
IF: 8,216
Q: 1 D: 1

Rivero-Juarez A, Gonzalez R, Frias M, Manzanares-Martin B, Rodriguez-Cano D, Perez-Camacho I, Gordon A, Cuenca F, Camacho A, Pineda JA, Pena J, Rivero A. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. PHARMACOGENOMICS JOURNAL. 2017. 17(4):360-365.
IF: 3,815
Q: 1

Brieva T, Rivero A, Rivero-Juarez A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2017.13(4):483-490.
IF: 3,027
Q: 2

Cuenca-Lopez F, Rivero A, Rivero-Juarez A. Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2017.13(1):105-112.
IF: 3,027
Q: 2

Risalde MA, Rivero-Juarez A, Romero-Palomo F, Frias M, Lopez-Lopez P, Cano-Terriza D, Garcia-Bocanegra I, Jimenez-Ruiz S, Camacho A, Machuca I, Gomez-Villamandos JC, Rivero A. Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar. PLOS ONE. 2017. 12(11):-e0186858.
IF: 2,806
Q: 1

Frias M, Rivero-Juarez A, Tellez F, Perez-Perez M, Camacho A, Machuca I, Lorenzo-Moncada S, Lopez-Lopez P, Rivero A. Grp Estudio Hepatitis Virales HEPA; SAEI. Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy. PLOS ONE. 2017. 12(5):-e0177141.
IF: 2,806
Q: 1

Rivero-Juarez A, Lopez-Cortes LF, Castano M, Merino D, Marquez M, Mancebo M, Cuenca-Lopez F, Jimenez-Aguilar P, Lopez-Montesinos I, Lopez-Cardenas S, Collado A, Lopez-Ruz MA, Omar M, Tellez F, Perez-Stachowski X, Hernandez-Quero J, Giron-Gonzalez JA, Fernandez-Fuertes E, Rivero A. SAEI. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2017.36(3):487-494.
IF: 2,727
Q: 2

Rivero-Juarez A, Frias M, Martinez-Peinado A, Risalde MA, Rodriguez-Cano D, Camacho A, Garcia-Bocanegra I, Cuenca-Lopez F, Gomez-Villamandos JC, Rivero A. Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption. ZOONOSES AND PUBLIC HEALTH. 2017. 64(7):561-565.
IF: 2,323
Q: 1 D: 1

Risalde MA, Thomas J, Sevilla I, Serrano M, Ortiz JA, Garrido J, Dominguez M, Dominguez L, Gortazar C, Ruiz-Fons JF. Development and evaluation of an interferon gamma assay for the diagnosis of tuberculosis in red deer experimentally infected with Mycobacterium bovis. BMC VETERINARY RESEARCH. 2017. 13():-341.
IF: 1,75
Q: 1

Rivero A, Moreno S. Is it time to start new HIV prevention strategies in Spain? ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2017. 35(5):271-272.
IF: 1,714
Q: 3

Moreno S, Antela A, Garcia F, del Amo J, Boix V, Coll P, Fortuny C, Sirvent JLG, Gutierrez F, Iribarren JA, Llibre JM, de Quiros JCLB, Losa JE, Lozano A, Meulbroek M, Olalla J, Pujol F, Pulido F, Casal MC, Garcia JG, Aldeguer JL, Molina JAP, Palter DP, Roman AR. Grp Redactor GESIDA SEIMC. Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2017.35(6):377-383.
IF: 1,714
Q: 3

Macias J, Mancebo M, Merino D, Tellez F, Montes-Ramirez ML, Pulido F, Rivero-Juarez A, Raffo M, Perez-Perez M, Merchante N, Cotarelo M, Pineda JA.Spanish AIDS Res Network-HEChanges in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. CLINICAL INFECTIOUS DISEASES. 2017.65(6):1012-1019.
IF: 8,216
Q: 1 D: 1

Pulido F, Ribera E, Lagarde M, Perez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodriguez-Gomez FJ, Tellez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR.DUAL-GESIDA-8014-RIS-EST45 Study G. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. CLINICAL INFECTIOUS DISEASES. 2017. 65(12):2112-2118.
IF: 8,216
Q: 1 D: 1

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suarez-Lozano I, Riera M, Estebanez M, Palacios R, Sanz-Moreno J, Troya J, Marino A, Antela A, Navarro J, Esteban H, Moreno S, GeSIDA 7011 Study Grp. Simplification to dual therapy (atazanavir/ritonavir plus lamivudine) versus standard triple therapy [atazanavir/ritonavir plus two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2017. 72(1):246-253.
IF: 5,071
Q: 1

Merchante N, Rivero-Juarez A, Tellez F, Merino D, Rios-Villegas MJ, Ojeda-Burgos G, Omar M, Macias J, Rivero A, Perez-Perez M, Raffo M, Lopez-Montesinos I, Marquez-Solero M, Gomez-Vidal MA, Pineda JA.SAEI. Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. AIDS. 2017. 31(4):493-500.
IF: 5,003
Q: 1

Merchante N, Ibarra S, Revollo B, Rodriguez-Arrondo F, Merino E, Delgado-Fernandez M, Montero-Alonso M, Tellez F, Galindo MJ, Rivero-Juarez A, Garcia MA, Minguez C, Romero-Palacios A, Garcia-Deltoro M, Pineda JA.GEHEP-002 Study Grp. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. AIDS. 2017. 31(1):89-95.
IF: 5,003
Q: 1

Nuñez-Torres R, Macias J, Rivero-Juarez A, Neukam K, Merino D, Tellez F, Merchante N, Gomez-Mateos J, Rivero A, Pineda JA, Real LM. Andalusian Soc Infectious Dis SAEI. Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. HIV MEDICINE. 2017.18(8):546-554.
IF: 3,257
Q: 2

Garcia-Bocanegra I, Cano-Terriza D, Vidal G, Rosell R, Paniagua J, Jimenez-Ruiz S, Exposito C, Rivero-Juarez A, Arenas A, Pujols J. Monitoring of Schmallenberg virus in Spanish wild artiodactyls, 2006-2015. PLOS ONE. 2017. 12(8):-e0182212.
IF: 2,806
Q: 1

Neukam K, Morano-Amado LE, Rivero-Juarez A, Macias J, Granados R, Romero-Palacios A, Marquez M, Merino D, Ortega E, Alados-Arboledas JC, Cucurull J, Omar M, Ryan-Murua P, Pineda JA, Soc Espanola Enfermedade, Soc Andaluza Enfermedades Infecc, HEPAVIR RED Invest SIDA RIS-HEP07. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2017. 36(5):853-861.
IF: 2,727
Q: 2

Thomas J, Risalde MA, Serrano M, Sevilla I, Geijo M, Ortiz JA, Fuertes M, Ruiz-Fons JF, de la Fuente J, Dominguez L, Juste R, Garrido J, Gortazar C. The response of red deer to oral administration of heat-inactivated Mycobacterium bovis and challenge with a field strain. VETERINARY MICROBIOLOGY. 2017. 208():195-202.
IF: 2,628
Q: 1 D: 1

Arboledas JCA, Guerrero IP, Rodriguez MJB, Martos ET, Perez AB, Leon CC, Sanchez JFS, Prieto MDL, Porcuna NC, Mochon MDO, Macias J, Salgado AD, Granger JR, Fernandez MD, Lozano IG, Ramirez ER, Rivero A, Dominguez MDL, Viciana I, Montemayor JCG, Garcia FG. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2017.89(1):29-34.
IF: 2,401
Q: 3

Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Cote P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu ZH, Mendez P, Hughes E, Noviello S, Ackerman P. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. HEPATOLOGY INTERNATIONAL. 2017.11(2):188-198.
IF: 2,164
Q: 3

Saumoy M, Llibre JM, Terron A, Knobel H, Arribas JR, Domingo P, Arroyo-Manzano D, Rivero A, Moreno S, Podzamczer D. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2017. 33(1):29-32.
IF: 2,095
Q: 3

Neukam K, Morano-Amado LE, Rivero-Juarez A, Mancebo M, Granados R, Tellez F, Collado A, Rios MJ, de los Santos-Gil I, Reus-Banuls S, Vera-Mendez F, Geijo-Martinez P, Montero-Alonso M, Suarez-Santamaria M, Pineda JA. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV CLINICAL TRIALS. 2017. 18(3):126-134.
IF: 1,778
Q: 3

Crespo M, Navarro J, Moreno S, Sanz J, Marquez M, Zamora J, Ocampo A, Iribaren JA, Rivero A, Llibre JM. Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2017. 35(8):491-496.
IF: 1,714
Q: 3

Clinical Research

Active in 2019

Estudio de fase III, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/Emtricitabina/Tenofovir Alafenamida en comparación con Abacavir/Dolutegravir/Lamivudina en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo.
PI: Dr. Antonio Rivero Román

Estudio de fase III, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de GS-9883/Emtricitabina/Tenofovir Alafenamida en comparación con Dolutegravir+Emtricitabina/Tenofovir Alafenamida en adultos infectados por el VIH-1 sin tratamiento antirretroviral previo.
PI: Dr. Antonio Rivero Román

A Phase III, randomised, double-find, multicentre, parallelgroup, non-inferiority study evaluating the efficacy, safety, and tolerability of Dolutegravir plus Lamivudine compared to Dolutegravir plus Tenofovir/Emtricitabine in HIV-1-infected treatment-naive adults.
PI: Dr. Antonio Rivero Román

Estudio fase III aleatorizado, multicéntrico abierto, de grupos paralelos, de no inferioridad, para evaluar la eficacia, seguridad y tolerabilidad del cambio de una terapia antirretroviral basada en INI, ITINN o IP a una pauta de tratamiento intremuscular de acción prolongada con Cabotegravir y Rilpivirina en pacientes adultos infectados por el VIH-1 con supresión virológica. A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to Long-acting Cabotegravir Plus long-acting Rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed.
PI: Dr. Antonio Rivero Román

Estudio fase IIIb, aleatorizado, multicéntrico, abierto, de grupos paralelos, de no inferioridad que evalúa la eficacia, seguridad y tolerabilidad de Cabotegravir de acción prolongada más Rilpivirina de acción prolongada administrados cada 8 semanas o cada 4 semanas en adultos infectados por VIH-1 que presentan supresión virológica.
PI: Dr. Antonio Rivero Román

Ensayo clínico piloto, multicéntrico, para comparar la eficacia de RTG 1200 QD vs DRV-cb (800-150) QD ambos en combinación con TAF/FTC en pacientes con infección VIH y CD4<200 cél/microL.
PI: Dr. Antonio Rivero Román

SYMTRI Study: Ensayo clínico abierto, aleatorizado y multicéntrico para comparar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento TAF/FTC/DRV/cobi vs. ABC/3TC/DTG en pacientes infectados por el VIH-1 naïve de tratamiento antirretroviral.
PI: Dr. Antonio Rivero Román

Estudio de fase IV, multicéntrico, abierto y aleatorizado, para evaluar el impacto del cambio de tratamiento antirretroviral de terapia dual a terapia triple sobre la inflamación en pacientes con infección por VIH tipo 1.
PI: Dr. Antonio Rivero Román

Cohorte española de pacientes con infección por VIH mayores de 50 años para el estudio de fragilidad y la función física. (HIV-FUNCFRAIL).
PI: Dr. Isabel María Machuca Sánchez

Cohorte de seguimiento propsectiva de los pacientes con hepatopía crónica VHC genotipo 1 y 3 con respuesta viral sostenida a los antivirales de acción directa libres de interferón, coinfectados y no coinfectados por el VIH.
PI: Dr. Antonio Rivero Román

Ensayo en fase III, randomizado, controlado con tratamiento activo y doble ciego para evaluar la eficacia y seguridad del régimen combinado de Darunavir/Cobicistat/Emtricitabina/Tenofovir Alafenamida (D/C/F/TAF) administrado una vez al día frente al régimen consistente en la combinación de Darunavir/Cobicistat coadministrado junto con la combinación Emtricitabina/Tenofovir Disoproxil Fumarato en sujetos naive en tratamiento antirretroviral infectados por el virus de la inmunodeficiencia humana de tipo 1.
PI: Dr. Antonio Rivero Román

Estudio en fase III, aleatorizado y doble ciego para evaluar la seguridad y eficacia del cambio de un régimen formado por Dolutegravir y ABC/3TC, o una combinación de dosis fijas (CDF) de ABC/DTG/3TC a una CDF de GS 9883/F/TAF en sujetos infectados por el VIH-1 con supresión virológica.
PI: Dr. Antonio Rivero Román

Research groups